Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effect of Thiazolidinedione Treatment Vascular Risk Markers
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 25
- Registration Number
- NCT00571506
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2008-11-25
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 20
- Registration Number
- NCT00570622
- Locations
- 🇦🇹
Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 143
- Registration Number
- NCT00554853
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 15
- Registration Number
- NCT00545857
- Locations
- 🇺🇸
Thomas A. Wilson, MD, Stony Brook, New York, United States
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT00545233
Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00531882
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 518
- Registration Number
- NCT00521820
Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 300
- Registration Number
- NCT00521742
Influence of Pioglitazone for Renal Transplant Function in Diabetics
- Conditions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2011-10-28
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00507494
- Locations
- 🇩🇪
Nephrology, Department of Medicine, university hospital Dresden, Dresden, Germany
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
- Conditions
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 334
- Registration Number
- NCT00500331
- Locations
- 🇿🇦
GSK Investigational Site, Roodepoort, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.